Global Hospital-Acquired Infection Control Market 2017-2021

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

• Overview

PART 05: Market landscape

• Overview
• Market size and forecast
• Five forces analysis

PART 06: Segmentation by infection type

• Overview
• CAUTIs
• SSIs
• CLABSIs
• Respiratory infections

PART 07: Segmentation by end-user

• Overview
• Hospitals and ICUs
• Outpatient care centers
• LTCFs
• Others

PART 08: Segmentation by geography

• Overview
• Americas
• EMEA
• APAC

PART 09: Decision framework

PART 10: Drivers and challenges

• Market drivers
• Market challenges

PART 11: Market trends

• Emergence of innovative techniques to remove biofilms
• Decrease in regulatory approvals of antibiotics
• Focus on early diagnosis and preventive medicine
• Cost burden of HAIs on patients and hospitals

PART 12: Vendor landscape

• Competitive scenario

PART 13: Key vendor analysis

• AstraZeneca
• GlaxoSmithKline
• Merck
• Pfizer
• Other prominent vendors

PART 14: Appendix

• List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

• Manufacturers and suppliers
• Channel partners
• Industry experts
• Strategic decision makers

Secondary sources

• Industry journals and periodicals
• Government data
• Financial reports of key industry players
• Historical data
• Press releases

DATA ANALYSIS

Data Synthesis

• Collation of data
• Estimation of key figures
• Analysis of derived insights

Data Validation

• Triangulation with data models
• Reference against proprietary databases
• Corroboration with industry experts

REPORT WRITING